The license will allow CannaCure to begin selling cannabis products, including oil derivatives, directly to provincial cannabis boards in Canada
Heritage Cannabis Holdings Corp () () (FRA:2UE) said its subsidiary, CannaCure Corp, has been granted a cannabis oil sales license effective October 9, by regulators at Health Canada, that will allow it to begin selling cannabis products, including oil derivatives, directly to provincial cannabis boards.
The approval will complement several products that Heritage already offers through its other subsidiary, Voyage Cannabis Corp, including Pura Vida cannabidiol (CBD) 4:1 Honey Oil, and Indica, Sativa and Hybrid Honey Oil vape cartridges, as well as Purefarma Moon, Sun and Earth vape cartridges. Tinctures include Pura Vida ‘Daybreak’ and ‘Nightfall’ full-spectrum THC tinctures and the Purefarma Hemplixer full-spectrum CBD tinctures in two concentrations, HLX15 and HLX30.
READ: Heritage Cannabis closes acquisition of cannabinoid company Opticann; building on US expansion strategy
“Having the CannaCure sales license granted by Health Canada is another accomplishment for the Heritage team and follows on recent positive news of our acquisition of Opticann Inc., and the availability of our products through the medical site Patient Choice. We are on a strong trajectory in the Canadian and U.S. cannabis markets and having our sales license at CannaCure provides the optionality and flexibility for the business as we continue on our successful path,” Heritage chief executive Clint Sharples said in a statement.
Heritage is a vertically integrated cannabis provider that operates through its subsidiaries and provides them with resources to advance their product ranges to compete domestically in the Canadian market and internationally.
Contact the author at [email protected]
Follow him on Twitter @Cal_Proac
